Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports

Shuwa Halima Ali; Aliyu Dorcas; Okwume Chukwudi Crescent; Animasaun Olawale Sunday; Ogar Christopher; Bello Zakariyya Muhammad; Adekola Hafeez Aderinsayo; Emeribe Chinenye Helen; Usman Yahaya; Awoniyi Luqman O; Ghamba Peter Elisha; Rogo Lawal Dahiru; Nwofe Justin Onyebuchi; Olayemi Lawal; Chiwar Hassan Musa; Fasogbon Samuel Ayobami; Abdullahi Idris Nasir; Emeribe Anthony Uchenna; Musa Sanusi; Haruna Shamsuddeen; Uzairue Leonard; Gwarzo Abubakar Muhammad; Muhammad Habiba Yahaya; Anka Abubakar Umar; Musa Bolanie OP

Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports

Shuwa Halima Ali
Aliyu Dorcas
Okwume Chukwudi Crescent
Animasaun Olawale Sunday
Ogar Christopher
Bello Zakariyya Muhammad
Adekola Hafeez Aderinsayo
Emeribe Chinenye Helen
Usman Yahaya
Awoniyi Luqman O
Ghamba Peter Elisha
Rogo Lawal Dahiru
Nwofe Justin Onyebuchi
Olayemi Lawal
Chiwar Hassan Musa
Fasogbon Samuel Ayobami
Abdullahi Idris Nasir
Emeribe Anthony Uchenna
Musa Sanusi
Haruna Shamsuddeen
Uzairue Leonard
Gwarzo Abubakar Muhammad
Muhammad Habiba Yahaya
Anka Abubakar Umar
Musa Bolanie OP
Katso/Avaa
ihab005.pdf (710.0Kb)
Lataukset: 

OXFORD UNIV PRESS
doi:10.1093/inthealth/ihab005
URI
https://doi.org/10.1093/inthealth/ihab005
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022081154188
Tiivistelmä
As the coronavirus disease 2019 (COVID-19) pandemic continues to rise and second waves are reported in some countries, serological test kits and strips are being considered to scale up an adequate laboratory response. This study provides an update on the kinetics of humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and performance characteristics of serological protocols (lateral flow assay [LFA], chemiluminescence immunoassay [CLIA] and ELISA) used for evaluations of recent and past SARS-CoV-2 infection. A thorough and comprehensive review of suitable and eligible full-text articles was performed on PubMed, Scopus, Web of Science, Wordometer and medRxiv from 10 January to 16 July 2020. These articles were searched using the Medical Subject Headings terms 'COVID-19', 'Serological assay', 'Laboratory Diagnosis', 'Performance characteristics', 'POCT', 'LFA', 'CLIA', 'ELISA' and 'SARS-CoV-2'. Data from original research articles on SARS-CoV-2 antibody detection >= second day postinfection were included in this study. In total, there were 7938 published articles on humoral immune response and laboratory diagnosis of COVID-19. Of these, 74 were included in this study. The detection, peak and decline period of blood anti-SARS-CoV-2 IgM, IgG and total antibodies for point-of-care testing (POCT), ELISA and CLIA vary widely. The most promising of these assays for POCT detected anti-SARS-CoV-2 at day 3 postinfection and peaked on the 15th day; ELISA products detected anti-SARS-CoV-2 IgM and IgG at days 2 and 6 then peaked on the eighth day; and the most promising CLIA product detected anti-SARS-CoV-2 at day 1 and peaked on the 30th day. The most promising LFA, ELISA and CLIA that had the best performance characteristics were those targeting total SARS-CoV-2 antibodies followed by those targeting anti-SARS-CoV-2 IgG then IgM. Essentially, the CLIA-based SARS-CoV-2 tests had the best performance characteristics, followed by ELISA then POCT. Given the varied performance characteristics of all the serological assays, there is a need to continuously improve their detection thresholds, as well as to monitor and re-evaluate their performances to assure their significance and applicability for COVID-19 clinical and epidemiological purposes.
Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste